(firstQuint)Pharmacokinetics of Apremilast (CC-10004) in Healthy Elderly Subjects.

 This is an open-label, parallel group study where eligible elderly subjects (aged 65-85 years inclusive) and younger subjects (aged 18-55 years inclusive) and who are matched to the elderly subjects by sex and BMI ( 10%) will receive a single dose of 30 mg apremilast under fasting conditions.

 The subjects will check into the study center on Day -1, will be dosed on Day 1, and discharged from the study center on Day 3 after all scheduled pharmacokinetic blood draws and safety evaluations.

.

 Pharmacokinetics of Apremilast (CC-10004) in Healthy Elderly Subjects@highlight

The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics, and the safety of a single oral dose of 30 mg of apremilast in healthy subjects.

